Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$27.49
-$0.80(-3.25%)
At close: 4:00 PM EST
$27.49
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $27.92
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.46M
Market Cap
$5.45B
Enterprise Value$4.54B
Total Cash (Recent Filing)$994.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Jun 03, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding203,532,180
10 Day Avg. Volume1,515,389
30 Day Avg. Volume1,456,267
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-44.99K
Enterprise Value/Ebitda-9.44
Forecast
1Y Price Target
$37.63Price Target Upside36.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Regulatory PathwayPositive efficacy signals from batoclimab and IMVT-1402, including strong responses in uncontrolled Graves' disease and cutaneous lupus, could support regulatory submissions and expand the commercial opportunity.
Enrollment MomentumFaster-than-expected enrollment in the difficult-to-treat rheumatoid arthritis study demonstrates operational execution and strong patient and investigator interest, de-risking near-term clinical timelines.
Product DifferentiationIMVT-1402 is designed to deliver deeper, dose-dependent IgG suppression than current competitors, positioning the candidate to be first- and best-in-class in difficult-to-treat autoimmune diseases such as rheumatoid arthritis and cutaneous lupus.
Bears Say
Dosing Regimen RiskThe trial dosing strategy reduces dose intensity after the initial treatment period, which could dilute the measured effect at the primary assessment and complicate interpretation of Phase 3 efficacy.
Financial Risk And Short InterestHigh short interest combined with elevated cash burn increases the risk of shareholder dilution or selling pressure if clinical milestones are delayed or missed.
Trial Design RiskAbsence of a pre-specified futility analysis in the Phase 3 trials raises the chance of prolonged exposure to ineffective arms and greater uncertainty around study outcomes.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $27.92 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $5.45B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jun 03, 2026 which is in 113 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2026. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$0.713 by $0.103.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.64.
How many shares outstanding does Immunovant have?
Immunovant has 203,532,180 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.61 in its last earnings report, beating expectations of -$0.713. Following the earnings report the stock price went up 12.427%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.63 (36.87% Upside)
$37.63 (36.87% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $349.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.85%
12-Months-Change
Fundamentals
Return on Equity
-69.35%
Trailing 12-Months
Asset Growth
150.01%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum driven by exceptionally strong Phase II brepocitinib data in cutaneous sarcoidosis, multiple fully enrolled studies and a solid cash position to fund upcoming registrational activity. Key operational highlights include the brepo NDA in dermatomyositis, fully enrolled 1402 D2T RA and mosliciguat PH‑ILD studies, and constructive legal progress ahead of a March jury trial. Offsetting risks are the small size and baseline imbalances of the CS Phase II study (creating uncertainty aboutPhase III translation), ongoing litigation and evidentiary motions, continued high operating spend and typical regulatory/development timing uncertainties. Overall, the positives (clinical wins, pipeline momentum, enrollment success and cash runway) materially outweigh the programmatic and legal uncertainties identified on the call.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$37.63
▲(36.87% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---